Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Digoxin.

Eric J Eichhorn1, Mihai Gheorghiade

  • 1Cardiac Catheterization Laboratory and Department of Internal Medicine, Dallas Veterans Administration Hospital and University of Texas Southwestern Medical Center, Dallas, TX, USA.

Progress in Cardiovascular Diseases
|May 15, 2002
PubMed
Summary

Digoxin remains a valuable treatment for heart failure and atrial fibrillation, offering cost-effective rate control and inotropic support without increasing mortality. It is particularly useful for patients with systolic heart failure or atrial fibrillation unresponsive to other therapies.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cancer Therapy-Related Cardiac Dysfunction and Heart Failure: Part 1: Definitions, Pathophysiology, Risk Factors, and Imaging.

Circulation. Heart failure·2016
Same author

Temporal Changes in Postdischarge Mortality Risk After Hospitalization for Heart Failure (from the EVEREST Trial).

The American journal of cardiology·2016
Same author

Partial adenosine A1 receptor agonism: a potential new therapeutic strategy for heart failure.

Heart failure reviews·2015
Same author

Myocardial Fibrosis Quantified by Extracellular Volume Is Associated With Subsequent Hospitalization for Heart Failure, Death, or Both Across the Spectrum of Ejection Fraction and Heart Failure Stage.

Journal of the American Heart Association·2015
Same author

Spectrum of epidemiological and clinical findings in patients with heart failure with preserved ejection fraction stratified by study design: a systematic review.

European journal of heart failure·2015
Same author

Letter by Abu Daya et al Regarding Article, "Myocardial Stiffness in Patients With Heart Failure and a Preserved Ejection Fraction, Contributions of Collagen and Titin".

Circulation·2015

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Digitalis has been used for over 200 years.
  • ACE inhibitors and beta-blockers offer proven survival benefits in heart failure.
  • Digoxin is an established treatment for heart failure and atrial fibrillation.

Purpose of the Study:

  • To evaluate the continued role of digitalis (digoxin) in managing heart failure and atrial fibrillation.
  • To highlight the benefits of digoxin, including its low cost and safety profile.
  • To define specific patient populations that may benefit from digoxin therapy.

Main Methods:

  • Review of existing literature and clinical guidelines regarding digoxin use.
  • Analysis of digoxin's efficacy and safety in heart failure and atrial fibrillation.
  • Comparison of digoxin with other standard therapies like ACE inhibitors and beta-blockers.

Related Experiment Videos

Main Results:

  • Digoxin is an inexpensive and well-tolerated oral inotrope that does not increase mortality in heart failure patients, especially at low doses.
  • It remains a viable option for heart failure and atrial fibrillation management.
  • Digoxin is particularly beneficial for patients with systolic heart failure or atrial fibrillation with uncontrolled symptoms despite other treatments.

Conclusions:

  • Digoxin therapy is cost-effective and safe for specific patient groups.
  • It plays a crucial role in managing heart failure and atrial fibrillation, especially for rate control.
  • Digoxin should be considered for patients with systolic heart failure or atrial fibrillation who require additional therapeutic options.